IL18 and chronic myelogenous leukemia, BCR-ABL1 positive: Importantly, IL-18 has also been implicated in activating ILC2 responses in chronic myeloid leukemia and prostate cancer (9, 15) promoting immune suppression and tumor progression, raising the possibility that similar mechanisms may be involved also in thymic carcinoma.